Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors.

Best practice & research. Clinical haematology - 1 Sept 2003

Gilliland D Gary

Abstract excerpt

Our understanding of the genetic basis of acute myeloid leukaemias has been enhanced through cloning of recurring chromosomal translocation breakpoints. However, the remarkable observation, more than a decade ago, that all-trans retinoic acid (ATRA) induced remission in patients with t(15;17) acu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Activation
Share to Enzyme Inhibitors
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Promyelocytic, Acute

Share to Neoplasm Proteins

Share to Oncogene Proteins, Fusion

Share to Proto-Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 12935959
DOI: 10.1016/s1521-6926(03)00063-x

Genes

FLT3
PML

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12935959-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors.PMID 12935959Read ↗

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657Semantic proximity Read ↗

Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion GeneSemantic proximity Read ↗

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesSemantic proximity Read ↗

Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusionsSemantic proximity Read ↗

Recent advances in acute promyelocytic leukaemiaSemantic proximity Read ↗

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesSemantic proximity Read ↗

Acute promyelocytic leukemia: from highly fatal to highly curableSemantic proximity Read ↗

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.Semantic proximity Read ↗

Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.Semantic proximity Read ↗

How retinoic acid and arsenic transformed acute promyelocytic leukemia therapySemantic proximity Read ↗

Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.Semantic proximity Read ↗

Current views on the genetic landscape and management of variant acute promyelocytic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.